G2GBIO Company Description

G2GBIO Inc., a clinical-stage biotech company, provides pharmaceutical products.

The company’s pipeline products includes GB-5001, GB-5001A, and GB-5112 for the treatment of alzheimer’s disease; GB-6002, an opioid drug that is used for post-operative pain treatment; GB-7001 for type-2 diabetes treatments; GB-5313 for the treatment of Osteoarthritis; GB-7101 and GB-7103 for the treatment of prostate cancer; GB-6201 and GB-6203 for androgenetic alopecia treatments; and GH-001 for the treatment of Hepatitis B.

It also develops GB-2001 for animal castration; and GB-2006, an animal postoperative pain relief drug, which is in clinical trial stage.

The company was founded in 2017 and is headquartered in Cheongju-si, South Korea.

G2GBIO Inc.

Country	South Korea
Founded	2017
Industry	Pharmaceutical Preparations
CEO	Hee-yong Lee

Contact Details

Address: 21, Uiryodanji-gil Cheongju-si South Korea
Phone	82 4 3270 6000
Website	g2gbio.com

Stock Details

Ticker Symbol	456160
Exchange	KOSDAQ
Reporting Currency	KRW
SIC Code	2834

Key Executives

Name	Position
Hee-yong Lee	Chief Executive Officer